571186-91-9 Usage
Description
Imatinib (Piperidine)-N-oxide, also known as Imatinib impurity D, is a pale yellow solid that is identified as an impurity of Imatinib (Gleevec) (G407000). It is a derivative of Imatinib, a medication used to treat certain types of cancer, and has been found to have potential applications in various fields, including pharmaceutical research and development.
Uses
Used in Pharmaceutical Research and Development:
Imatinib (Piperidine)-N-oxide is used as an impurity in the development and manufacturing process of Imatinib (Gleevec), a medication used to treat various types of cancer. Its presence as an impurity allows researchers to study its effects and potential interactions with the main compound, which can contribute to the optimization of the drug's formulation and efficacy.
Used in COVID-19 Research:
Imatinib (Piperidine)-N-oxide is also used as a COVID-19-related research product. Its potential applications in this field may include the study of its interactions with the virus or its role in the development of new treatments or therapies for COVID-19.
Used as a Metabolite of Imatinib:
As a metabolite of Imatinib, Imatinib (Piperidine)-N-oxide plays a role in the body's processing and elimination of the drug. Studying its properties and behavior can provide valuable insights into the pharmacokinetics and pharmacodynamics of Imatinib, which can help in the development of more effective and safer medications for cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 571186-91-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,7,1,1,8 and 6 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 571186-91:
(8*5)+(7*7)+(6*1)+(5*1)+(4*8)+(3*6)+(2*9)+(1*1)=169
169 % 10 = 9
So 571186-91-9 is a valid CAS Registry Number.
InChI:InChI=1/C29H31N7O2/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-35-14-16-36(2,38)17-15-35/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
571186-91-9Relevant articles and documents
Investigations into the potential role of metabolites on the anti-leukemic activity of imatinib, nilotinib and midostaurin
Manley, Paul W.
, p. 561 - 570 (2019/09/03)
The efficacy and side-effects of drugs do not just reflect the biochemical and pharmacodynamic properties of the parent compound, but often comprise of cooperative effects between the properties of the parent and active metabolites. Metabolites of imatinib, nilotinib and midostaurin have been synthesised and evaluated in assays to compare their properties as protein kinase inhibitors with the parent drugs. The N-desmethylmetabolite of imatinib is substantially less active than imatinib as a BCR-ABL1 kinase inhibitor, thus providing an explanation as to why patients producing high levels of this metabolite show a relatively low response rate in chronic myeloid leukaemia (CML) treatment. The hydroxymethylphenyl and N-oxide metabolites of imatinib and nilotinib are only weakly active as BCR-ABL1 inhibitors and are unlikely to play a role in the efficacy of either drug in CML. The 3-(R)-HO-metabolite of midostaurin shows appreciable accumulation following chronic drug administration and, in addition to mutant forms of FLT3, potently inhibits the PDPK1 and VEGFR2 kinases (IC50 values 100 nM), suggesting that it might contribute to drug efficacy in acute myeloid leukaemia patients. The case studies discussed here provide further examples of how the synthesis and characterisation of metabolites can make important contributions to understanding the clinical efficacy of drugs.